Individualizing dosing frequency may improve the efficacy of prophylaxis in patients with von Willebrand disease—a WIL-31 subanalysis
Background: The efficacy and safety of prophylaxis with wilate, a plasma-derived von Willebrand factor/factor VIII concentrate, was demonstrated in patients with von Willebrand disease of all types in the WIL-31 study. Objectives: To investigate the reasons for and the impact of changing the dosing...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2025-10-01
|
| Серія: | Research and Practice in Thrombosis and Haemostasis |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S247503792500545X |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|